[Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs].
Treatment strategies in patients with life-threatening ventricular tachyarrhythmias (i.e. sustained ventricular tachycardia, ventricular fibrillation, aborted sudden cardiac death) are changing. Amiodarone and d,l-sotalol, chosen by electrophysiologic study guidance, can be considered as drugs of choice for the pharmacological treatment. Compared to these agents, which both have additional electrophysiologic effects, the new pure class III agents seem to be less effective. With regard to antiarrhythmic efficacy, clinical trials comparing the long-term efficacy of antiarrhythmic agents and the implantable cardioverter/defibrillator are under way. Preliminary results indicate that the implantable cardioverter/defibrillator may provide superior outcome with regard to sudden cardiac death compared to the use of class III agents.